![](https://i2.wp.com/hrnxt.com/wp-content/uploads/2021/07/acquisition.jpg?resize=200%2C112&ssl=1)
Biocon Biologics, a unique, fully integrated, global biosimilars company with a rich portfolio of insulins and monoclonal antibodies, has successfully concluded the integration of the acquired Viatris biosimilars business with the transition of 10+ Emerging Markets and Japan, Australia and New Zealand in the final phase. All Viatris’ biosimilars brands, including Ogivri & Hertraz (bTrastuzumab), Abevmy (bBevacizumab), Fulphila (bPegfilgrastim), Hulio (bAdalimumab), Nepexto…